|Bid||229.50 x 800|
|Ask||237.16 x 800|
|Day's Range||226.77 - 230.99|
|52 Week Range||197.75 - 286.72|
|Beta (5Y Monthly)||0.84|
|PE Ratio (TTM)||83.94|
|Forward Dividend & Yield||3.16 (1.38%)|
|Ex-Dividend Date||Dec 09, 2020|
|1y Target Est||N/A|
The many of us who are unwilling to leave our homes to get a coronavirus test now have a home testing solution authorized by the Food and Drug Administration. The agency announced earlier this week that it has granted Emergency Use Authorization (EUA) for in-home use to Lucira Health's COVID-19 All-In-One test kit. According to Lucira, a privately held company, the test is a single-use prescription product.
Generation Investment Management releases quarterly portfolio
This should further boost BD's (BDX) Medical segment.